Cargando…
GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA
BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263156/ http://dx.doi.org/10.1093/neuonc/noab090.064 |
_version_ | 1783719328520077312 |
---|---|
author | McNutt, Sarah Shah, Nidhi Rizk, Elias |
author_facet | McNutt, Sarah Shah, Nidhi Rizk, Elias |
author_sort | McNutt, Sarah |
collection | PubMed |
description | BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive immature teratoma is variable, and can include surgery, chemotherapy and/or craniospinal radiation. Case: 10 year old boy with precocious puberty presented to the local Emergency room with tonic-clonic seizures. Imaging showed a localized pineal mass, with mixed cystic and solid components. Biopsy results were diagnostic for mixed germ cell tumor with components of immature teratoma. Prior to the start of chemotherapy, serum and cerebrospinal fluid (CSF) tumor markers showed slight elevation of both alpha feto- protein (AFP) and beta-human chorionic gonadotropin hormone (β-HCG). The patient underwent two cycles of chemotherapy per ACNS1123, stratum 1, with normalization of tumor markers. Unfortunately, near the end of Cycle 2 of chemotherapy, patient presented with clinical signs of herniation, and was noted to have significant progression of pineal mass on imaging. Tumor was gross totally resected, with pathology conclusive for only immature teratoma. Pre- and post-operative tumor markers remained normal. Proton-beam craniospinal radiation was then administered. Patient is now almost 6 months off therapy, with unremarkable serum and CSF tumor markers, as well as serial imaging that remains negative for disease, with neurological development appropriate for age. CONCLUSION: This case highlights the unusual nature of progression of an immature teratoma with no elevation of tumor markers while on chemotherapy. While salvage chemotherapy, in the form of a metronomic regimen or high-dose consolidative regimen, can be considered, these do present quite a bit of short-term and long-term toxicity to the growing child. Craniospinal irradiation followed by close monitoring is a reasonable alternative, with less short-term toxicity, for an entity that is radio-sensitive. |
format | Online Article Text |
id | pubmed-8263156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82631562021-07-08 GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA McNutt, Sarah Shah, Nidhi Rizk, Elias Neuro Oncol Germ Cell Tumors BACKGROUND: Localized NGGCT, a heterogeneous entity, treated with chemo-radiotherapy harbors an overall survival of around 93% based. Here, we present a case of a child whose immature teratoma progressed on chemotherapy, while tumor markers remain within normal range. Salvage therapy for progressive immature teratoma is variable, and can include surgery, chemotherapy and/or craniospinal radiation. Case: 10 year old boy with precocious puberty presented to the local Emergency room with tonic-clonic seizures. Imaging showed a localized pineal mass, with mixed cystic and solid components. Biopsy results were diagnostic for mixed germ cell tumor with components of immature teratoma. Prior to the start of chemotherapy, serum and cerebrospinal fluid (CSF) tumor markers showed slight elevation of both alpha feto- protein (AFP) and beta-human chorionic gonadotropin hormone (β-HCG). The patient underwent two cycles of chemotherapy per ACNS1123, stratum 1, with normalization of tumor markers. Unfortunately, near the end of Cycle 2 of chemotherapy, patient presented with clinical signs of herniation, and was noted to have significant progression of pineal mass on imaging. Tumor was gross totally resected, with pathology conclusive for only immature teratoma. Pre- and post-operative tumor markers remained normal. Proton-beam craniospinal radiation was then administered. Patient is now almost 6 months off therapy, with unremarkable serum and CSF tumor markers, as well as serial imaging that remains negative for disease, with neurological development appropriate for age. CONCLUSION: This case highlights the unusual nature of progression of an immature teratoma with no elevation of tumor markers while on chemotherapy. While salvage chemotherapy, in the form of a metronomic regimen or high-dose consolidative regimen, can be considered, these do present quite a bit of short-term and long-term toxicity to the growing child. Craniospinal irradiation followed by close monitoring is a reasonable alternative, with less short-term toxicity, for an entity that is radio-sensitive. Oxford University Press 2021-06-01 /pmc/articles/PMC8263156/ http://dx.doi.org/10.1093/neuonc/noab090.064 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Germ Cell Tumors McNutt, Sarah Shah, Nidhi Rizk, Elias GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title | GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title_full | GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title_fullStr | GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title_full_unstemmed | GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title_short | GERM-02. MANAGEMENT STRATEGY FOR CHEMO-REFRACTORY, PROGRESSIVE PEDIATRIC IMMATURE TERATOMA |
title_sort | germ-02. management strategy for chemo-refractory, progressive pediatric immature teratoma |
topic | Germ Cell Tumors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263156/ http://dx.doi.org/10.1093/neuonc/noab090.064 |
work_keys_str_mv | AT mcnuttsarah germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma AT shahnidhi germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma AT rizkelias germ02managementstrategyforchemorefractoryprogressivepediatricimmatureteratoma |